Keyphrases
Graft-versus-host Disease (GvHD)
100%
Acute Myeloid Leukemia
69%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
66%
Hematopoietic Cell Transplantation
51%
Post-transplantation Cyclophosphamide (PTCy)
48%
Unrelated Donor
40%
Overall Survival
39%
Confidence Interval
39%
Haploidentical
38%
Hazard Ratio
38%
Non-relapse Mortality
38%
Myelodysplastic Syndrome
28%
Transplantation
27%
Donor Age
25%
Natural Killer Cells
23%
Busulfan
23%
High Risk
21%
Graft-versus-host Disease Prophylaxis
19%
Older Patients
19%
Fludarabine
19%
Multiple Myeloma
18%
HLA-matched Donor
18%
Conditioning Regimen
17%
Haploidentical Hematopoietic Stem Cell Transplantation
16%
Transplant Outcomes
16%
Cord Blood Transplantation
16%
Donor Type
16%
Autologous Transplantation
15%
Cord Blood
15%
Myeloablative
15%
Progression-free Survival
15%
Peripheral Blood
14%
Unrelated Hematopoietic Stem Cell Transplantation
14%
Multivariate Analysis
13%
Lower Gastrointestinal Tract
12%
Haploidentical Donor
12%
Matched Unrelated
12%
Unrelated Donor Transplantation
12%
Bone Marrow
12%
Clonal Hematopoiesis
11%
Matched Related
11%
Haploidentical Transplantation
10%
Hematological Malignancies
10%
Tacrolimus
10%
Hematopoietic Stem Cell Transplantation
10%
Engraftment
9%
Double Cord Blood Transplantation
9%
Improved Outcomes
9%
Acute Leukemia
9%
Platelet Engraftment
9%
Medicine and Dentistry
Hematopoietic Cell
85%
Cell Transplantation
83%
Acute Myeloid Leukemia
60%
Overall Survival
49%
Graft Versus Host Reaction
43%
Transplantation
38%
Acute Graft Versus Host Disease
35%
Myelodysplastic Syndrome
34%
Hazard Ratio
25%
Multiple Myeloma
24%
Chronic Graft Versus Host Disease
23%
Conditioning
23%
Progression Free Survival
22%
Cord Blood
21%
Stem Cell Transplant
20%
Busulfan
20%
Cyclophosphamide
20%
Malignant Neoplasm
19%
Fludarabine
16%
Diseases
16%
Allograft
13%
Alternative Donor
13%
Acute Lymphoblastic Leukemia
12%
Natural Killer Cell
12%
Comorbidity
12%
Hematopoietic Stem Cell Transplantation
12%
Hematopoiesis
11%
Cord Blood Stem Cell Transplantation
11%
Cancer
11%
Multivariate Analysis
11%
Acute Myelogenous Leukemia
11%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Engraftment
11%
Non-Relapse Mortality
10%
Donor Selection
10%
Allogeneic Stem Cell Transplantation
10%
Recurrence Free Survival
9%
Prophylaxis
9%
Melphalan
8%
Acute Leukemia
8%
Leukemia
8%
Cytomegalovirus
8%
Venetoclax
7%
Autotransplantation
7%
Chimeric Antigen Receptor
7%
Bronchiolitis Obliterans
7%
T Cell
7%
Mortality Rate
7%
Neoplasm
7%
Platelet
6%
Immunology and Microbiology
Hematopoietic Cell
97%
Cell Transplantation
87%
Graft-Versus-Host Disease
71%
Cyclophosphamide
50%
Myeloid
48%
Overall Survival
41%
Conditioning
35%
Cord Blood Stem Cell Transplantation
35%
Chronic Graft Versus Host Disease
34%
Natural Killer Cell
30%
Acute Graft Versus Host Disease
29%
Engraftment
22%
Progression Free Survival
21%
Multiple Myeloma
19%
Umbilical Cord Blood
17%
Allograft
15%
Recurrence Free Survival
13%
Platelet
11%
Neutrophil
10%
Donor Selection
10%
Immune Reconstitution
10%
Tacrolimus
9%
Drug Megadose
9%
Cytomegalovirus
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Killer-Cell Immunoglobulin-Like Receptor
9%
Hematopoietic Stem Cell Transplantation
8%
Peptides
7%
Allogeneic Stem Cell Transplantation
7%
Haplotype
7%
Chimeric Antigen Receptor
7%
B Cell
7%
T Cell
7%
Human Leukocyte Antigen
6%
Mycophenolate Mofetil
5%
Comorbidity
5%
CD19
5%
Inflammatory Cytokine
5%
Stem Cell
5%
Methotrexate
5%
Immunotherapy
5%